Checkpoint Therapeutics, Inc.
CKPT
$4.04
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | 32.26% | -- | -91.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -- | 32.26% | -- | -91.89% |
| Cost of Revenue | 102.54% | 15.83% | -67.87% | -46.31% | -41.70% |
| Gross Profit | -102.69% | -16.49% | 68.10% | 46.19% | 41.44% |
| SG&A Expenses | 540.72% | 50.18% | -2.06% | 6.94% | -24.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 183.33% | 25.76% | -58.62% | -39.57% | -39.14% |
| Operating Income | -183.50% | -26.27% | 58.80% | 39.46% | 38.90% |
| Income Before Tax | -51.09% | -69.90% | 59.63% | -4.50% | 9.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -51.09% | -69.90% | 59.63% | -4.50% | 9.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.09% | -69.90% | 59.63% | -4.50% | 9.01% |
| EBIT | -183.50% | -26.27% | 58.80% | 39.46% | 38.90% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 8.93% | 21.30% | 82.65% | 62.71% | 66.26% |
| Normalized Basic EPS | 8.93% | 21.28% | 82.65% | 62.72% | 66.26% |
| EPS Diluted | 8.93% | 21.30% | 82.65% | 62.71% | 66.26% |
| Normalized Diluted EPS | 8.93% | 21.28% | 82.65% | 62.72% | 66.26% |
| Average Basic Shares Outstanding | 65.91% | 115.89% | 132.65% | 180.29% | 169.69% |
| Average Diluted Shares Outstanding | 65.91% | 115.89% | 132.65% | 180.29% | 169.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |